Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 57th annual scientific meeting of the British Society of Haematology (BSH) will be held in Brighton, UK on March 27-29, 2017. The scientific and educational program will cover the latest research and best practice in hematology.

BSH 2017

27–29 March 2017 | Brighton, UK

BSH 2017

27–29 March 2017 | Brighton, UK

The 57th annual scientific meeting of the British Society of Haematology (BSH) will be held in Brighton, UK on March 27-29, 2017. The scientific and educational program will cover the latest research and best practice in hematology.

Future treatment options for multiple myeloma 1:39
Future treatment options for multiple myeloma
Karthik Ramasamy • 27 Mar 2017
The practicality of prescribing and administering biosimilars 2:52
The practicality of prescribing and administering biosimilars
Steve Williamson • 27 Mar 2017
Physicians concerns on the use of biomsimilars 3:41
Physicians concerns on the use of biomsimilars
Steve Williamson • 27 Mar 2017
The GALLIUM study 2:23
The GALLIUM study
Robert Marcus • 27 Mar 2017
Managing and predicting TLS in CLL patients 1:00
Managing and predicting TLS in CLL patients
Peter Hillmen • 27 Mar 2017
Promising novel treatments in multiple myeloma 2:20
Promising novel treatments in multiple myeloma
Paul Richardson • 27 Mar 2017
Issues for patients surrounding brand changes 1:09
Issues for patients surrounding brand changes
Martin Dyer • 27 Mar 2017
New trials in relapsed high-grade lymphomas 1:41
New trials in relapsed high-grade lymphomas
Graham Collins • 27 Mar 2017
Venetoclax in combination with antibodies in the treatment of CLL 2:10
Venetoclax in combination with antibodies in the treatment of CLL
John Gribben • 27 Mar 2017
Resistance mechanisms of current treatments in CLL 2:43
Resistance mechanisms of current treatments in CLL
John Gribben • 27 Mar 2017
Current treatment options for CLL 4:52
Current treatment options for CLL
John Gribben • 27 Mar 2017
Development of blood clots in multiple myeloma patients treated with immunomodulatory drugs 1:25
Development of blood clots in multiple myeloma patients treated with immunomodulatory drugs
Karthik Ramasamy • 27 Mar 2017
What are the causes of fatigue after cancer treatment? 3:02
What are the causes of fatigue after cancer treatment?
Marije van der Lee • 27 Mar 2017
The use of trastuzumab and biosimilars in the treatment of breast cancer 1:47
The use of trastuzumab and biosimilars in the treatment of breast cancer
Mark Verrill • 27 Mar 2017
Advantages of using biosimilars 1:42
Advantages of using biosimilars
Mark Verrill • 27 Mar 2017
Combining venetoclax and obinutuzumab in the treatment of CLL 3:22
Combining venetoclax and obinutuzumab in the treatment of CLL
Martin Dyer • 27 Mar 2017

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals